Search
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalCopanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell surviva...
Thiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalIt has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]
Products: TIOCOLCHICOSIDE DOC GENERICI, TIOCOLCHICOSIDE MYLAN GENERICSZileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnThese effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.
Categories: Agents to Treat Airway DiseaseVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalVilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity.
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalIt is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease.
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnProsomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384]. … Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin.
Nalorphine
go.drugbank.com/drugs/DB11490ExperimentalVet approvedIt is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence. … It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.
Eniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’